Literature DB >> 21730274

A time to keep and a time to cast away categories of tumor response.

Michael L Maitland, Robert R Bies, Jeffrey S Barrett.   

Abstract

Entities:  

Mesh：

Year:  2011        PMID： 21730274     DOI： 10.1200/JCO.2011.36.3887

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN： 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  8 in total

1.  Incorporating biomarkers into clinical trial designs: points to consider.

Authors:  Edward Bradley
Journal:  Nat Biotechnol       Date:  2012-07-10       Impact factor: 54.908

2.  Vol-PACT: A Foundation for the NIH Public-Private Partnership That Supports Sharing of Clinical Trial Data for the Development of Improved Imaging Biomarkers in Oncology.

Authors:  Laurent Dercle; Dana E Connors; Ying Tang; Stacey J Adam; Mithat Gönen; Patrick Hilden; Sanja Karovic; Michael Maitland; Chaya S Moskowitz; Gary Kelloff; Binsheng Zhao; Geoffrey R Oxnard; Lawrence H Schwartz
Journal:  JCO Clin Cancer Inform       Date:  2018-12

Review 3.  Cancer pharmacogenomics: strategies and challenges.

Authors:  Heather E Wheeler; Michael L Maitland; M Eileen Dolan; Nancy J Cox; Mark J Ratain
Journal:  Nat Rev Genet       Date:  2012-11-27       Impact factor: 53.242

4.  Tumor growth rate is an early indicator of antitumor drug activity in phase I clinical trials.

Authors:  Charles Ferté; Marianna Fernandez; Antoine Hollebecque; Serge Koscielny; Antonin Levy; Christophe Massard; Rastislav Balheda; Brian Bot; Carlos Gomez-Roca; Clarisse Dromain; Samy Ammari; Jean-Charles Soria
Journal:  Clin Cancer Res       Date:  2013-11-15       Impact factor: 12.531

5.  Evaluation of a novel rash scale and a serum proteomic predictor in a randomized phase II trial of sequential or concurrent cetuximab and pemetrexed in previously treated non-small cell lung cancer.

Authors:  Michael L Maitland; Matthew R Levine; Mario E Lacouture; Kristen E Wroblewski; Christine H Chung; Ilyssa O Gordon; Livia Szeto; Gail Ratko; Keyoumars Soltani; Mark F Kozloff; Philip C Hoffman; Ravi Salgia; David P Carbone; Theodore G Karrison; Everett E Vokes
Journal:  BMC Cancer       Date:  2014-01-04       Impact factor: 4.430

6.  Simulations to Predict Clinical Trial Outcome of Bevacizumab Plus Chemotherapy vs. Chemotherapy Alone in Patients With First-Line Gastric Cancer and Elevated Plasma VEGF-A.

Authors:  K Han; L Claret; Y Piao; P Hegde; A Joshi; J R Powell; J Jin; R Bruno
Journal:  CPT Pharmacometrics Syst Pharmacol       Date:  2016-07-12

7.  Novel Tumor Growth Rate Analysis in the Randomized CLARINET Study Establishes the Efficacy of Lanreotide Depot/Autogel 120 mg with Prolonged Administration in Indolent Neuroendocrine Tumors.

Authors:  Clarisse Dromain; Arturo Loaiza-Bonilla; Beloo Mirakhur; Thomas J R Beveridge; Antonio Tito Fojo
Journal:  Oncologist       Date:  2021-02-01

8.  Comparative Effects of CT Imaging Measurement on RECIST End Points and Tumor Growth Kinetics Modeling.

Authors:  C H Li; R R Bies; Y Wang; M R Sharma; S Karovic; L Werk; M J Edelman; A A Miller; E E Vokes; A Oto; M J Ratain; L H Schwartz; M L Maitland
Journal:  Clin Transl Sci       Date:  2016-01-21       Impact factor: 4.689
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.